Oxis International Inc. (OTC:OXIS)
Industry: Healthcare

OFF LIST - 1425 consecutive market days: OFF LIST as of 10/07/2010 Through 11/14/2016

OXIS International, Inc., through its subsidiary, Oxis Biotech, Inc., discovers, develops, and commercializes therapeutics from its proprietary product platform in various disease areas in the United States. The company is developing drugs focused on the treatment of cancer. Its lead drug candidates include OXS-2175, a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer; OXS-4235, a small molecule therapeutic candidate to treat multiple myeloma and associated osteolytic lesion; and OXS-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors. The company was formerly known as DDI Pharmaceuticals, Inc. and changed its name to Oxis International, Inc. in 1994. Oxis International, Inc. was founded in 1965 and is based in Tampa, Florida.

Current Quote*
Last: $0.094
Change: -0.007
Book: $1.000
Volume: 20,593,179

As Of: 08/16 13:13 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol OXIS

Graphs for OXIS


3 Month Graph


6 Month Graph


1 Year Graph